Sienna Gestion Reduces Stock Position in Eli Lilly and Company (NYSE:LLY)

Sienna Gestion lessened its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,450 shares of the company's stock after selling 2,090 shares during the quarter. Eli Lilly and Company accounts for 1.2% of Sienna Gestion's portfolio, making the stock its 14th largest position. Sienna Gestion's holdings in Eli Lilly and Company were worth $14,812,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LLY. WestEnd Advisors LLC boosted its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the last quarter. Citizens National Bank Trust Department raised its holdings in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $40,000. Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $43,000. Finally, O Brien Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $660.41 on Thursday. The firm's 50 day moving average is $767.52 and its two-hundred day moving average is $796.25. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.53. The firm has a market capitalization of $625.05 billion, a P/E ratio of 43.16, a PEG ratio of 0.90 and a beta of 0.44. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the business earned $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Analyst Ratings Changes

Several equities research analysts recently commented on LLY shares. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday. Finally, HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $964.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.